HTLT GLP Max - 60 Capsules

GLP Max | Appetite Suppressant

Stimulant Free 

Decrease your appetite by using the cutting edge science of the gut-brain axis (how your gut and brain work together)

Environmental and intrinsic factors affect the gut biome, the milieu of nutrients present in the large intestine greatly affect hunger signalling. These factors play a crucial role in telling our body when to put the fork down.

The most cutting edge weight-loss agents used in clinical practice are those which reduce food intake by modulating satiety neuropeptide activity like GLP-1 / GIP receptor agonists (semaglutide, tirzapetide amongst others).

GLP Max set out to answer this problem by using natural compounds which have shown favorable safety profiles and compelling evidence in reducing food intake & promoting weight-loss, through multifaceted mechanisms which involve increasing the activity of endogenous satiety hormones.

Ingredients 

Hops Flower Extract 10:1 (Humulus lupulus)

Hops is a plant which contains bitter compounds that have shown the ability to decrease food intake in both animals and human models, even amongst lean and healthy individuals [1].

In a recent randomized controlled trial on 30 healthy women (BMI 18.5–25 kg/m2), administration of hops extract orally led to reduced hunger and food cravings in participants undergoing an acute 24 h fast [1].

Without conscious effort and instructions to eat until satisfied, the participants in the Hops group reduced their food intake by 14.3% following a 24 hour fast (compared to placebo) [1]. The experimental (hops) group also reported a reduction in cravings for savory and sweet foods compared to placebo [1].

In another randomized controlled trial assessing the effect of hops extract on satiety in healthy-weight men, the treatment also led to a significant reduction in food intake, stimulated prelunch ghrelin, postprandial cholecystokinin, glucagon-like peptide 1, and peptide YY secretion compared to placebo (these neuropeptides promote fullness and reduce food intake) [2].

The above trials used a delayed release capsule for gut targeted administration, where we were also careful to use the exact same capsule (DR Caps) in GLP Max to insure the same gut-targeted effect.

Visual analogue scale (VAS) results for hunger and fullness throughout the day in response to placebo, low dose (LD) and high dose (HD) Hops Extract treatments. Changes (Δ) in the ratings of (a) hunger and (c) fullness. Histograms show AUCΔ0–510 min for Δ with respect to (b) hunger and (d) fullness [1].

L-Lysine Butyrate (BIOMEnd ©)

Butyrate is a short chain fatty acid which is a fermentation by-product of dietary fiber in the gut microbiome [3]. Butyrate possesses unique cell-signalling properties which have shown effects of decreasing insulin resistance in humans, increasing GLP1 production by intestinal cells & the liver, while also sensitizing our body to the effects of GLP-1 [3].

In a randomized controlled trial assessing the effects of butyrate in obese children, there was a consistent response which showed a significant reduction of bodyweight and waist circumference compared to placebo [4]. Per-protocol analysis in the butryate group revealed a decrease in BMI of 2.26 units and a reduction in waist circumference by 5.07cm in 6 months [4].

Berberine HCl

Berberine is an isoquinoline alkaloid found in the roots and rhizomes of various medicinal plants, with an extensive history for managing type 2 diabetes [5].

In a literature review by Araj-Khodaei et al., it was stated that Berberine induces GLP-1 insulin secretion by altering the gut biome, and promoting the secretion of short chain fatty acids in the large intestine [6].

Akkermansia muciniphilia

Akkermansia muciniphilia (A. muciniphilia) is an intestinal anaerobe which finds itself in the human digestive tract very early on in life [7].

In a recent double-blind randomized controlled trial, supplementation of A. muciniphilia for three months in obese participants demonstrated improved insulin sensitivity (+28.62 ± 7.02%, P = 0.002), and reduced insulinemia (−34.08 ± 7.12%, P = 0.006) compared to placebo [9]. These effect sizes are not only statistically significant, they are also clinically significant and quite impressive for just administration of a single ingredient. This was a proof of concept study and we will update this page as more human literature is published investigating the metabolic effects of A. muciniphilia supplementation.

It was found that in obese individuals undergoing weight-loss, greater fecal A. muciniphila concentration was associated with a healthier metabolic status and better clinical outcomes after caloric restriction in overweight/obese adults [8].

Probiotic Blend

(Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus gasseri, Lactobacillus paracasei, Lactobacillus fermentum, Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus salivarius, Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium infatis, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium bifidum)

Alterations in gut biome diversity is thought to play a pivotal role in the development of obesity [10]. In a randomized clinical trial evaluating the effects of multi-strain probiotic supplementation in overweight women diagnosed with food addiction, probiotic administration significantly reduced weight, body mass index, waist circumference and body fat percentage compared to the placebo group (p < 0.001) [10]. The participants were also observed to have a significant improvement in eating behavior in the probiotic group compared to the placebo group (p <0.001) [10].

In a meta analysis and systematic review by Noormohammadi et al, it was found that multi probiotic/symbiotic administration in humans promoted a significant reduction in leptin (indicating improvement in leptin resistance), as well as an increase in adiponectin levels (an insulin sensitizing hormone) [11].

*These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease.

References
Walker, E., Lo, K., & Gopal, P. (2024). Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obesity pillars, 11, 100117. https://doi.org/10.1016/j.obpill.2024.100117

Walker, E. G., Lo, K. R., Pahl, M. C., Shin, H. S., Lang, C., Wohlers, M. W., Poppitt, S. D., Sutton, K. H., & Ingram, J. R. (2022). An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. The American journal of clinical nutrition, 115(3), 925–940. https://doi.org/10.1093/ajcn/nqab418

Zhou, D., Chen, Y. W., Zhao, Z. H., Yang, R. X., Xin, F. Z., Liu, X. L., Pan, Q., Zhou, H., & Fan, J. G. (2018). Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Experimental & molecular medicine, 50(12), 1–12. https://doi.org/10.1038/s12276-018-0183-1

Coppola, S., Nocerino, R., Paparo, L., Bedogni, G., Calignano, A., Di Scala, C., de Giovanni di Santa Severina, A. F., De Filippis, F., Ercolini, D., & Berni Canani, R. (2022). Therapeutic Effects of Butyrate on Pediatric Obesity: A Randomized Clinical Trial. JAMA network open, 5(12), e2244912. https://doi.org/10.1001/jamanetworkopen.2022.44912

Wenguang Chang, Non-coding RNAs and Berberine: A new mechanism of its anti-diabetic activities, European Journal of Pharmacology, Volume 795, 2017, Pages 8-12, ISSN 0014-2999,

https://doi.org/10.1016/j.ejphar.2016.11.055

Araj-Khodaei, M., Ayati, M. H., Azizi Zeinalhajlou, A., Novinbahador, T., Yousefi, M., Shiri, M., Mahmoodpoor, A., Shamekh, A., Namazi, N., & Sanaie, S. (2024). Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review. Archives of physiology and biochemistry, 130(6), 678–685. https://doi.org/10.1080/13813455.2023.2258559

Abuqwider, J. N., Mauriello, G., & Altamimi, M. (2021). Akkermansia muciniphila, a New Generation of Beneficial Microbiota in Modulating Obesity: A Systematic Review. Microorganisms, 9(5), 1098. https://doi.org/10.3390/microorganisms9051098

Fonseca, E., Quintana, L., & Pérez-Matos, M. C. (2016). A double-blind, placebo-controlled, randomized trial of probiotics for primary prevention of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Gut, 65(3), 426-435. https://gut.bmj.com/content/65/3/426

Depommier, C., Everard, A., Druart, C., Plovier, H., Van Hul, M., Vieira-Silva, S., Falony, G., Raes, J., Maiter, D., Delzenne, N. M., de Barsy, M., Loumaye, A., Hermans, M. P., Thissen, J. P., de Vos, W. M., & Cani, P. D. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature medicine, 25(7), 1096–1103. https://doi.org/10.1038/s41591-019-0495-2

Narmaki, E., Borazjani, M., Ataie-Jafari, A., Hariri, N., Doost, A. H., Qorbani, M., & Saidpour, A. (2022). The combined effects of probiotics and restricted calorie diet on the anthropometric indices, eating behavior, and hormone levels of obese women with food addiction: a randomized clinical trial. Nutritional neuroscience, 25(5), 963–975. https://doi.org/10.1080/1028415X.2020.1826763

Noormohammadi, M., Ghorbani, Z., Löber, U., Mahdavi-Roshan, M., Bartolomaeus, T. U. P., Kazemi, A., Shoaibinobarian, N., & Forslund, S. K. (2023). The effect of probiotic and synbiotic supplementation on appetite-regulating hormones and desire to eat: A systematic review and meta-analysis of clinical trials. Pharmacological research, 187, 106614. https://doi.org/10.1016/j.phrs.2022.106614